AAPG
ASCENTAGE PHARMA GROUP INTERNATIONAL
NASDAQ · Healthcare · Biotechnology · CN
$17.62
+1.47%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.0B | 558.5M | 980.6M | 222.0M | 209.7M |
| Cost of Revenue | 152.4M | 131.7M | 29.1M | 30.5M | 22.0M |
| Gross Profit | 871.2M | 426.7M | 951.6M | 191.4M | 187.7M |
| Operating Expenses | |||||
| R&D Expense | 2.3B | 1.1B | 947.2M | 707.0M | 743.1M |
| SG&A Expense | 1.1B | 522.7M | 383.1M | 376.5M | 328.0M |
| General & Admin Expense | 199.8M | — | 187.1M | 181.1M | 170.6M |
| Selling & Marketing Expense | 244.1M | — | 196.0M | 195.4M | 157.4M |
| Other Expenses | — | 6.99 | (9.1M) | (19.4M) | (33.6M) |
| Total Operating Expenses | 3.4B | 1.6B | 1.3B | 1.1B | 1.0B |
| Cost and Expenses | 3.5B | 1.7B | 1.4B | 1.1B | 1.1B |
| Operating Income (EBIT) | (2.5B) | (1.2B) | (369.7M) | (872.6M) | (849.8M) |
| Non-Operating | |||||
| Interest Income | 90.4M | 79.9M | 37.8M | 32.4M | 9.7M |
| Interest Expense | 52.3M | 52.6M | 64.5M | 96.1M | 52.8M |
| Net Interest Income | 38.1M | 27.3M | (26.6M) | (63.6M) | (43.1M) |
| Other Non-Op Income/Expense | (71.1M) | (23.2M) | (25.5M) | (60.2M) | (37.4M) |
| Non-Operating Income (excl Interest) | — | — | (38.9M) | (35.8M) | (15.4M) |
| EBT (Pre-Tax Income) | (2.6B) | (1.2B) | (395.3M) | (932.9M) | (887.2M) |
| Income Tax Expense | 30.7M | 6.8M | 10.4M | (7.2M) | (4.2M) |
| Bottom Line | |||||
| Net Income | (2.6B) | (1.2B) | (405.4M) | (925.6M) | (882.9M) |
| Earnings from Cont. Ops | (2.6B) | (1.2B) | (405.7M) | (925.7M) | (882.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (2.6B) | (1.2B) | (405.4M) | (925.6M) | (882.9M) |
| Per Share | |||||
| Basic EPS | ($29.80) | ($13.56) | ($5.36) | ($52.48) | ($53.60) |
| Diluted EPS | ($29.80) | ($13.56) | ($5.36) | ($52.48) | ($53.60) |
| Revenue Per Share | $10.97 | $6.27 | $12.99 | $12.58 | $12.73 |
| Shares | |||||
| Basic Shares Outstanding | 93.3M | 89.0M | 75.5M | 17.6M | 16.5M |
| Diluted Shares Outstanding | 93.3M | 89.0M | 75.5M | 17.6M | 16.5M |
| Profitability Metrics | |||||
| EBITDA | (2.3B) | (1.1B) | (237.6M) | (743.6M) | (787.0M) |
| D&A | 163.1M | 84.1M | 93.2M | 93.2M | 47.4M |
| EBIT | (2.5B) | (1.2B) | (330.8M) | (836.8M) | (834.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026